130 related articles for article (PubMed ID: 36272185)
21. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
[TBL] [Abstract][Full Text] [Related]
22. The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential.
Michelfelder S; Fischer F; Wäldin A; Hörle KV; Pohl M; Parsons J; Reski R; Decker EL; Zipfel PF; Skerka C; Häffner K
J Am Soc Nephrol; 2018 Apr; 29(4):1141-1153. PubMed ID: 29335241
[TBL] [Abstract][Full Text] [Related]
23. Characterization of alternative pathway inhibition by a serum derived, low molecular weight complement inhibitor.
Baker PJ; Parker CJ; Osofsky SG
Clin Exp Immunol; 1984 Jan; 55(1):166-76. PubMed ID: 6559107
[TBL] [Abstract][Full Text] [Related]
24. Small-molecule factor B inhibitor for the treatment of complement-mediated diseases.
Schubart A; Anderson K; Mainolfi N; Sellner H; Ehara T; Adams CM; Mac Sweeney A; Liao SM; Crowley M; Littlewood-Evans A; Sarret S; Wieczorek G; Perrot L; Dubost V; Flandre T; Zhang Y; Smith RJH; Risitano AM; Karki RG; Zhang C; Valeur E; Sirockin F; Gerhartz B; Erbel P; Hughes N; Smith TM; Cumin F; Argikar UA; Haraldsson B; Mogi M; Sedrani R; Wiesmann C; Jaffee B; Maibaum J; Flohr S; Harrison R; Eder J
Proc Natl Acad Sci U S A; 2019 Apr; 116(16):7926-7931. PubMed ID: 30926668
[TBL] [Abstract][Full Text] [Related]
25. Structures of C3b in complex with factors B and D give insight into complement convertase formation.
Forneris F; Ricklin D; Wu J; Tzekou A; Wallace RS; Lambris JD; Gros P
Science; 2010 Dec; 330(6012):1816-20. PubMed ID: 21205667
[TBL] [Abstract][Full Text] [Related]
26. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
[TBL] [Abstract][Full Text] [Related]
27. The role of the alternative pathway in paroxysmal nocturnal hemoglobinuria and emerging treatments.
Lee JW; Brodsky RA; Nishimura JI; Kulasekararaj AG
Expert Rev Clin Pharmacol; 2022 Jul; 15(7):851-861. PubMed ID: 35980222
[TBL] [Abstract][Full Text] [Related]
28. Detection of C3 Nephritic Factor by Hemolytic Assay.
Chabannes M; Frémeaux-Bacchi V; Chauvet S
Methods Mol Biol; 2021; 2227():147-158. PubMed ID: 33847940
[TBL] [Abstract][Full Text] [Related]
29. Complement component C2, inhibiting a latent serine protease in the classical pathway of complement activation.
Halili MA; Ruiz-Gómez G; Le GT; Abbenante G; Fairlie DP
Biochemistry; 2009 Sep; 48(35):8466-72. PubMed ID: 19642650
[TBL] [Abstract][Full Text] [Related]
30. Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases.
Michels MAHM; van de Kar NCAJ; Okrój M; Blom AM; van Kraaij SAW; Volokhina EB; van den Heuvel LPWJ
Front Immunol; 2018; 9():612. PubMed ID: 29670616
[TBL] [Abstract][Full Text] [Related]
31. Functional Characterization of Alternative and Classical Pathway C3/C5 Convertase Activity and Inhibition Using Purified Models.
Zwarthoff SA; Berends ETM; Mol S; Ruyken M; Aerts PC; Józsi M; de Haas CJC; Rooijakkers SHM; Gorham RD
Front Immunol; 2018; 9():1691. PubMed ID: 30083158
[TBL] [Abstract][Full Text] [Related]
32. A reexamination of the role of magnesium in the human alternative pathway of complement.
Pryzdial EL; Isenman DE
Mol Immunol; 1986 Jan; 23(1):87-96. PubMed ID: 3634188
[TBL] [Abstract][Full Text] [Related]
33. Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation.
Chen JY; Galwankar NS; Emch HN; Menon SS; Cortes C; Thurman JM; Merrill SA; Brodsky RA; Ferreira VP
Front Immunol; 2020; 11():1460. PubMed ID: 32793201
[TBL] [Abstract][Full Text] [Related]
34. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3.
Pangburn MK; Schreiber RD; Müller-Eberhard HJ
J Exp Med; 1981 Sep; 154(3):856-67. PubMed ID: 6912277
[TBL] [Abstract][Full Text] [Related]
35. A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement.
Lindorfer MA; Pawluczkowycz AW; Peek EM; Hickman K; Taylor RP; Parker CJ
Blood; 2010 Mar; 115(11):2283-91. PubMed ID: 20068220
[TBL] [Abstract][Full Text] [Related]
36. Functional Hemolytic Test for Complement Alternative Pathway Convertase Activity.
Michels MAHM; van de Kar NCAJ; Volokhina EB; van den Heuvel BLPWJ
Methods Mol Biol; 2021; 2227():83-96. PubMed ID: 33847933
[TBL] [Abstract][Full Text] [Related]
37. Is generation of C3(H
Ekdahl KN; Mohlin C; Adler A; Åman A; Manivel VA; Sandholm K; Huber-Lang M; Fromell K; Nilsson B
Mol Immunol; 2019 Oct; 114():353-361. PubMed ID: 31446306
[TBL] [Abstract][Full Text] [Related]
38. Participation of C3 and its ligands in complement activation.
Volanakis JE
Curr Top Microbiol Immunol; 1990; 153():1-21. PubMed ID: 2404692
[TBL] [Abstract][Full Text] [Related]
39. C3 activation is inhibited by analogs of compstatin but not by serine protease inhibitors or peptidyl alpha-ketoheterocycles.
Furlong ST; Dutta AS; Coath MM; Gormley JJ; Hubbs SJ; Lloyd D; Mauger RC; Strimpler AM; Sylvester MA; Scott CW; Edwards PD
Immunopharmacology; 2000 Jul; 48(2):199-212. PubMed ID: 10936517
[TBL] [Abstract][Full Text] [Related]
40. A conserved element in the serine protease domain of complement factor B.
Hourcade DE; Mitchell LM; Oglesby TJ
J Biol Chem; 1998 Oct; 273(40):25996-6000. PubMed ID: 9748277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
